Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
BMJ Case Rep ; 14(4)2021 Apr 14.
Article in English | MEDLINE | ID: mdl-33853816

ABSTRACT

A 49-year-old man presented with a 1-week history of abdominal pain, distension, diarrhoea and fatigue. CT of the abdomen and pelvis revealed peritonitis with no identifiable cause. Diagnostic laparoscopy was performed, which excluded gastrointestinal perforation. Peritoneal fluid tested positive for Chlamydia trachomatis and rectal swabs were positive for C. trachomatis serovars consistent with lymphogranuloma venereum (LGV). Additional blood tests also revealed a diagnosis of syphilis. This is a rare documented case of LGV peritonitis in a male without associated immunodeficiency. The patient recovered well following laparoscopic washout and a course of appropriate antibiotics.


Subject(s)
Lymphogranuloma Venereum , Peritonitis , Anti-Bacterial Agents/therapeutic use , Chlamydia trachomatis , Homosexuality, Male , Humans , Lymphogranuloma Venereum/complications , Lymphogranuloma Venereum/diagnosis , Lymphogranuloma Venereum/drug therapy , Male , Middle Aged , Peritonitis/diagnosis , Peritonitis/drug therapy
2.
BMC Surg ; 17(1): 23, 2017 Mar 07.
Article in English | MEDLINE | ID: mdl-28270136

ABSTRACT

BACKGROUND: Centralisation of specialist surgical services requires that patients are referred to a regional centre for surgery. This process may disadvantage patients who live far from the regional centre or are referred from other hospitals by making referral less likely and by delaying treatment, thereby allowing tumour progression. The aim of this study is to explore the outcome of surgery for peri-ampullary cancer (PC) with respect to referring hospital and travel distance for treatment within a network served by five hospitals. METHODS: Review of a unit database was undertaken of patients undergoing surgery for PC between January 2006 and May 2014. RESULTS: 394 patients were studied. Although both the median travel distance for patients from the five hospitals (10.8, 86, 78.8, 54.7 and 89.2 km) (p < 0.05), and the annual operation rate for PC (2.99, 3.29, 2.13, 3.32 and 3.07 per 100,000) (p = 0.044) were significantly different, no correlation was noted between patient travel distance and population operation rate at each hospital. No difference was noted between patients from each hospital in terms of resection completion rate or pathological stage of the resected tumours. The median survival after diagnosis for patients referred from different hospitals ranged from 1.2 to 1.7 years and regression analysis revealed that increased travel distance to the regional centre was associated with a small survival advantage. CONCLUSION: Although variation in the provision and outcome of surgery for PC between regional hospitals is noted, this is not adversely affected by geographical isolation from the regional centre. TRIAL REGISTRATION: This study is part of post-graduate research degree project. The study is registered with ClinicalTrials.gov (unique identifier NCT02296736 ) November 18, 2014.


Subject(s)
Adenocarcinoma/mortality , Adenocarcinoma/surgery , Digestive System Neoplasms/mortality , Digestive System Neoplasms/surgery , Adult , Aged , Aged, 80 and over , Ampulla of Vater/surgery , Common Bile Duct Neoplasms/mortality , Common Bile Duct Neoplasms/surgery , Databases, Factual , Duodenal Neoplasms/mortality , Duodenal Neoplasms/surgery , Female , Health Services Accessibility/statistics & numerical data , Hospitals, Special/statistics & numerical data , Humans , Male , Middle Aged , Pancreatic Neoplasms/mortality , Pancreatic Neoplasms/surgery , Referral and Consultation , Survival Analysis , Treatment Outcome , United Kingdom/epidemiology
3.
HPB (Oxford) ; 18(7): 586-92, 2016 07.
Article in English | MEDLINE | ID: mdl-27346139

ABSTRACT

BACKGROUND: A period of recovery is commonly allowed between completion of chemotherapy for colorectal liver metastases (CRLM) and resection, during which tumour progression may occur. The study-aim is to assess the growth of CRLM in this interval and association with outcome. METHOD: Data on 146 patients were analysed. Change in tumour size was assessed by comparing size determined by imaging performed on completion of chemotherapy with that determined by examination of the resected specimen, categorised by RECIST criteria. RESULTS: In the interval before surgery sixteen patients (11%) fulfilled criteria for partial response (PR), 48 (33%) had stable disease (SD) and 82 (56%) had progressive disease (PD). Among patients with PD following chemotherapy the median disease-free survival of patients who initially responded (26 months) was longer than in those who initially had stable disease (7 months) (P = 0.002). No association was noted between rate of tumour growth after completion of chemotherapy and disease-free survival. CONCLUSION: Change in tumour size after completion of chemotherapy is variable and can be rapid, especially in patients who initially respond to treatment. However, disease-free survival is determined by tumour behaviour during treatment and not by change in size after completion of chemotherapy.


Subject(s)
Colorectal Neoplasms/pathology , Hepatectomy , Liver Neoplasms/secondary , Liver Neoplasms/therapy , Neoadjuvant Therapy , Adult , Aged , Aged, 80 and over , Chemotherapy, Adjuvant , Colorectal Neoplasms/mortality , Databases, Factual , Disease Progression , Disease-Free Survival , Female , Hepatectomy/adverse effects , Hepatectomy/mortality , Humans , Kaplan-Meier Estimate , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/mortality , Male , Middle Aged , Neoadjuvant Therapy/adverse effects , Neoadjuvant Therapy/mortality , Risk Factors , Time Factors , Tomography, X-Ray Computed , Treatment Outcome , Tumor Burden
4.
HPB (Oxford) ; 18(4): 354-9, 2016 Apr.
Article in English | MEDLINE | ID: mdl-27037205

ABSTRACT

BACKGROUND: Delay between diagnosis of peri-ampullary cancer (PC) and surgery may allow tumour progression and affect outcome. The aim of this study was to explore associations of interval to surgery (IS) with pathological outcomes and survival in patients with PC. METHOD: A database review of all patients undergoing surgery between 2006 and 2014 was undertaken. IS was measured from diagnosis by imaging. Potential association between IS and survival was measured using Cox regression analysis, and between IS and pathological outcome with multivariate logistic analysis. RESULTS: 388 patients underwent surgery. The median IS was 49 days (1-551 days), and was not associated with any of the evaluated outcomes in patients with pancreatic (149) or distal bile duct (46) cancer. For patients with ampullary cancer (71) longer IS was associated with improved survival, with median survival of 27.5 months for patients waiting ≤ median IS (35) and 38.3 months for patients waiting > median IS (36) for surgery (p = 0.041). A higher rate of margin positivity (31.4%) was also noted among patients who waited less than the median IS compared to those waiting longer than this interval (11.4%) (p = 0.032). CONCLUSION: For patients with ampullary cancer there is a paradoxical improvement in outcome among those with a longer IS, which may be explained by progression to inoperability of more aggressive lesions.


Subject(s)
Adenocarcinoma/surgery , Ampulla of Vater/surgery , Bile Duct Neoplasms/surgery , Duodenal Neoplasms/surgery , Pancreatic Neoplasms/surgery , Time-to-Treatment , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Adult , Aged , Aged, 80 and over , Ampulla of Vater/pathology , Bile Duct Neoplasms/mortality , Bile Duct Neoplasms/pathology , Chi-Square Distribution , Databases, Factual , Duodenal Neoplasms/mortality , Duodenal Neoplasms/pathology , Female , Humans , Kaplan-Meier Estimate , Logistic Models , Male , Middle Aged , Multivariate Analysis , Neoplasm, Residual , Odds Ratio , Pancreatic Neoplasms/mortality , Pancreatic Neoplasms/pathology , Proportional Hazards Models , Risk Factors , Time Factors , Treatment Outcome
5.
J Surg Res ; 198(1): 87-92, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26095422

ABSTRACT

BACKGROUND: Liver resection is associated with significant morbidity, and assessment of risk is an important part of preoperative consultations. Objective methods exist to assess operative risk, including cardiopulmonary exercise testing (CPX). Subjective assessment is also made in clinic, and patients perceived to be high-risk are referred for CPX at our institution. This article addresses clinicians' ability to identify patients with a higher risk of surgical complications after hepatectomy, using selection for CPX as a surrogate marker for increased operative risk. MATERIALS AND METHODS: Prospectively collected data on patients undergoing hepatectomy between February 2008 and November 2013 were retrieved and the cohort divided according to CPX referral. Complications were classified using the Clavien-Dindo system. RESULTS: CPX testing was carried out before 101 of 405 liver resections during the study period. The median age was 72 and 64 in CPX and non-CPX groups, respectively (P < 0.001). The resection size was similar between the groups. No difference was noted for grade III complications between CPX and non-CPX tested-groups; however, 19 (18.8%) and 28 (9.2%) patients suffered grade IV-V complications, respectively (P = 0.009). There was no difference in long-term survival between groups (P = 0.63). CONCLUSIONS: This study attempts to assess clinicians' ability to identify patients at greater risk of complications after hepatectomy. The confirmation that patients identified in this way are at greater risk of grade IV-V complications demonstrates the value of preoperative counseling. High-risk patients do not have worse long-term outcomes suggesting survival is determined by other factors, particularly disease recurrence.


Subject(s)
Exercise Test , Hepatectomy/adverse effects , Preoperative Care , Risk Assessment , Aged , Female , Humans , Male , Middle Aged , Prospective Studies
6.
Arch Surg ; 146(4): 471-8, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21502458

ABSTRACT

BACKGROUND: Postoperative complications are associated with a poor long-term prognosis after resection of colorectal liver metastases via an undetermined mechanism. The preoperative systemic inflammatory response, itself a predictor of poor survival, was recently shown to independently predict postoperative infectious complications after primary colorectal cancer resection. OBJECTIVE: To examine the association of postoperative infectious complications with preoperative systemic inflammation and survival in patients undergoing resection of colorectal liver metastases. DESIGN: Retrospective study based on a prospectively updated database. SETTING: A United Kingdom tertiary referral hepatobiliary unit. PATIENTS: A total of 202 consecutive patients with colorectal liver metastases undergoing hepatectomy between January 1, 2000, and April 30, 2006. MAIN OUTCOME MEASURES: Multivariable analyses were performed to correlate preoperative and operative variables with postoperative complications and to correlate complications with long-term survival after metastasectomy. RESULTS: Ninety-day mortality and morbidity were 2.0% and 25.7%, respectively. The preoperative systemic inflammatory response independently predicted the development of infectious complications (P = .009) and major infectious complications (P = .005) after hepatectomy, along with performance of trisectionectomy. Infectious complications were associated with poor long-term survival after metastasectomy but lost independent significance when systemic inflammatory variables were included in multivariable analyses. CONCLUSIONS: The preoperative systemic inflammatory response independently predicts the development of infectious complications after colorectal liver metastases resection. Although infectious complications are associated with adverse long-term prognosis after hepatectomy, they lacked independent prognostic value when systemic inflammatory variables were also considered, suggesting that much of their prognostic value arises from their association with the preoperative systemic inflammatory response.


Subject(s)
Colorectal Neoplasms/pathology , Hepatectomy/adverse effects , Infections/etiology , Liver Neoplasms/secondary , Liver Neoplasms/surgery , Postoperative Complications/etiology , Systemic Inflammatory Response Syndrome/complications , Adult , Aged , Disease-Free Survival , Female , Humans , Infections/epidemiology , Kaplan-Meier Estimate , Logistic Models , Male , Middle Aged , Multivariate Analysis , Postoperative Complications/classification , Postoperative Complications/epidemiology , Predictive Value of Tests , Preoperative Period , Prognosis , Proportional Hazards Models , Retrospective Studies , United Kingdom/epidemiology
7.
Surg Endosc ; 24(3): 567-71, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19609609

ABSTRACT

BACKGROUND: The British Society of Gastroenterology guidelines for the management of malignant obstructive jaundice state: "If a stent is placed prior to surgery, this should be of the plastic type and it should be placed endoscopically. Self-expanding metal stents should not be inserted in patients who are likely to proceed to resection." In 2003, a small series of complications after endoscopic intervention caused a change in the authors' practice. Currently, all patients requiring relief of biliary obstruction before surgical resection undergo attempted insertion of a short metal biliary stent. METHODS: Retrospective analysis of the authors' prospective database containing all patients presenting with periampullary and pancreatic tumors between January 2004 and May 2008 was performed. RESULTS: The authors have attempted percutaneous placement of internal metal stents in 67 patients with resectable malignancies and biliary obstruction. Stenting was successful for 53 patients (79%), and 5 patients (9.4%) experienced complications. These five patients were successfully managed conservatively, and all proceeded to trial dissection. The mean bilirubin level was 253 mg/dl before intervention and 33 mg/dl before surgery for the stented patients compared with 308 mg/dl before intervention and 102 mg/dl before surgery for those who needed external drainage. CONCLUSIONS: Percutaneous insertion of short metal stents provides a safe and effective alternative to endoscopic stent placement for treating jaundice preoperatively in patients with potentially resectable tumors around the pancreatic head.


Subject(s)
Biliary Tract Diseases/surgery , Aged , Aged, 80 and over , Biliary Tract Diseases/diagnostic imaging , Biliary Tract Diseases/etiology , Bilirubin/blood , Chi-Square Distribution , Drainage/methods , Female , Humans , Jaundice, Obstructive/complications , Jaundice, Obstructive/surgery , Male , Metals , Middle Aged , Pancreatic Neoplasms/complications , Pancreatic Neoplasms/surgery , Postoperative Complications , Radiography, Interventional , Retrospective Studies , Stents , Treatment Outcome
8.
J Gastrointest Surg ; 13(6): 1129-37, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19130151

ABSTRACT

BACKGROUND: Pancreatic resection is associated with a significant morbidity. Efforts to reduce hospital stay and enhance recovery have seen the introduction of minimally invasive surgical techniques. This article reviews the current published literature on the safety and efficacy of minimally invasive surgery of the pancreas. METHODS: An electronic search of the PubMed and Embase databases was performed from 1996 to May 2008 to identify all relevant publications; studies meeting predefined inclusion criteria were retrieved and analyzed using a standardized protocol. Data on the safety and efficacy of minimally invasive surgery of the pancreas were recorded and analyzed. RESULTS: Of 565 abstracts reviewed, 39 studies were identified as eligible for inclusion. There were 37 case series and two case control studies. Compared with open pancreatic surgery, minimally invasive pancreatic resection is similar in terms of morbidity and mortality. Blood loss and length of stay are decreased. CONCLUSIONS: Laparoscopic distal pancreatic resection and enucleation of insulinoma appear to be safe procedures with reduced hospital stay, though morbidity remains significant. The evidence for laparoscopic pancreaticoduodenectomy is in its infancy, but the authors feel it is unlikely that many centers will achieve sufficient case load to make the introduction of minimally invasive resection feasible.


Subject(s)
Minimally Invasive Surgical Procedures , Pancreatectomy/methods , Pancreatic Diseases/surgery , Blood Loss, Surgical/statistics & numerical data , Humans , Length of Stay/statistics & numerical data , Pancreaticoduodenectomy/methods , Postoperative Complications
9.
Eur J Cancer ; 45(1): 33-47, 2009 Jan.
Article in English | MEDLINE | ID: mdl-18938071

ABSTRACT

The worldwide incidence of cholangiocarcinoma (CC) is steadily rising, with the incidence in United Kingdom (UK) now exceeding 1000 cases per year. It is an aggressive malignancy typified by unresponsiveness to the existing chemotherapy and radiotherapy regimes in the vast majority of cases. Surgery offers the only hope of a cure, though post-operative disease recurrence is common, with 5-year survival rates of less than 25% following resection. Developments in molecular techniques and improved understanding of the basis of carcinogenesis in CC has led to examination of the role of biomarkers in predicting poor outcome. This systematic review examines published evidence relating to the prognostic significance of these molecular markers in CC. Of the molecular markers which have been investigated to date, p53 mutation, cyclins, proliferation indices, mucins, CA19-9, CRP and aneuploidy appear to hold significant potential as predictors of outcome in CC. These and other biomarkers may themselves represent novel therapeutic targets for CC.


Subject(s)
Bile Duct Neoplasms/genetics , Bile Ducts, Intrahepatic , Cholangiocarcinoma/genetics , Genes, Tumor Suppressor , Oncogenes , Antigens, Neoplasm/analysis , Apoptosis/genetics , Bile Duct Neoplasms/mortality , Biomarkers, Tumor/analysis , Cell Cycle Proteins/genetics , Cell Proliferation , Cholangiocarcinoma/mortality , Genetic Markers , Humans , Mucins/genetics , Prognosis
SELECTION OF CITATIONS
SEARCH DETAIL
...